Prokarium and ginkgo bioworks announce partnership to discover multiple targets for rna therapeutics and immuno-oncology

London and boston , jan. 9, 2023 /prnewswire/ -- prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop a bactofection platform to deliver rna-based therapeutics. most gene therapies today leverage viral delivery systems.
DNA Ratings Summary
DNA Quant Ranking